Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C O Bingham

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Circulation|January 1, 1990
Dual isotope thallium and indium antimyosin SPECT imaging to identify acute infarct patients at further ischemic riskL L Johnson, D W Seldin, A M Keller, et al.
The Journal of Biological Chemistry|October 26, 1999
Low molecular weight group IIA and group V phospholipase A(2) enzymes have different intracellular locations in mouse bone marrow-derived mast cellsC O Bingham, R J Fijneman, D S Friend, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 1999
Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cellsH Fujishima, R O Sanchez Mejia, C O Bingham, et al.
The Journal of Allergy and Clinical Immunology|July 10, 1999
The natural history of exercise-induced anaphylaxis: survey results from a 10-year follow-up studyN A Shadick, M H Liang, A J Partridge, et al.
Osteoarthritis and Cartilage|November 13, 2007
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trialP Garnero, W S Aronstein, S B Cohen, et al.
Rheumatology (Oxford, England)|August 29, 2006
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studiesC O Bingham, A I Sebba, B R Rubin, et al.
Arthritis and Rheumatism|March 6, 2012
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trialP P Tak, P J Mease, M C Genovese, et al.
Osteoarthritis and Cartilage|December 20, 2011
OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trialsR L Manno, C O Bingham, S Paternotte, et al.
Arthritis Care & Research|May 20, 2015
Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis PatientsJ R Curtis, S Yang, L Chen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 26, 2018
Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritisS J Bartlett, A K Gutierrez, A Butanis, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Circulation|January 1, 1990
Dual isotope thallium and indium antimyosin SPECT imaging to identify acute infarct patients at further ischemic riskL L Johnson, D W Seldin, A M Keller, et al.
The Journal of Biological Chemistry|October 26, 1999
Low molecular weight group IIA and group V phospholipase A(2) enzymes have different intracellular locations in mouse bone marrow-derived mast cellsC O Bingham, R J Fijneman, D S Friend, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 1999
Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cellsH Fujishima, R O Sanchez Mejia, C O Bingham, et al.
The Journal of Allergy and Clinical Immunology|July 10, 1999
The natural history of exercise-induced anaphylaxis: survey results from a 10-year follow-up studyN A Shadick, M H Liang, A J Partridge, et al.
Osteoarthritis and Cartilage|November 13, 2007
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trialP Garnero, W S Aronstein, S B Cohen, et al.
Rheumatology (Oxford, England)|August 29, 2006
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studiesC O Bingham, A I Sebba, B R Rubin, et al.
Arthritis and Rheumatism|March 6, 2012
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trialP P Tak, P J Mease, M C Genovese, et al.
Osteoarthritis and Cartilage|December 20, 2011
OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trialsR L Manno, C O Bingham, S Paternotte, et al.
Arthritis Care & Research|May 20, 2015
Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis PatientsJ R Curtis, S Yang, L Chen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 26, 2018
Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritisS J Bartlett, A K Gutierrez, A Butanis, et al.
Pageof 3